Chagas disease remains a significant public health concern, with limited treatment options and an urgent need for novel preventive strategies. Extracellular vesicles (EVs) from Trypanosoma cruzi have been shown to modulate host immune responses, often favoring parasite persistence. In this study, we characterized EVs derived from the non-pathogenic trypanosomatids Trypanosoma rangeli and Phytomonas serpens and evaluated their potential as immunogens capable of inducing cross-protection against T. cruzi infection. Isolated EVs were characterized by Nanoparticle Tracking Analysis (NTA) and electron microscopy. A comparative proteomic analysis of EVs was performed using Mass Spectrometry-Based Proteomic Analysis (LC-MS/MS). The effects of EVs on immunomodulation and T. cruzi infection were assessed through in vitro and in vivo assays, using peripheral blood mononuclear cells (PBMCs) and BALB/c mice. The proteomic analysis identified shared proteins between the EVs of T. rangeli, P. serpens, and T. cruzi, including immunogenic candidates such as calpain-like cysteine peptidase and elongation factor 2. In vitro, pre-stimulation with the T. rangeli EVs reduced infection rates of the host cells by T. cruzi. In vivo, immunization with the EVs from T. rangeli and P. serpens led to a significant reduction in parasitemia in the BALB/c mice challenged with T. cruzi, though this did not translate into improved survival compared to controls. Interestingly, the EVs from T. cruzi also reduced parasitemia but did not confer protection against mortality. These findings suggest that while non-pathogenic trypanosomatid EVs exhibit potential immunogenic properties and can reduce parasitic load, their efficacy in preventing disease progression remains limited. Further research is needed to explore the mechanisms underlying these effects and to optimize EV-based strategies for protective immunity against Chagas disease.

Diabetes mellitus prevalence is rising globally, linked to persistent hyperglycemia and endothelial dysfunction. Extracellular vesicles (EVs) play a role in diabetes pathology, involving complex intercellular communication that influences endothelial response. However, the mechanisms by which EVs contribute to endothelial dysfunction under hyperglycemia remain unknown. To investigate the effect of glucose-altered EVs on endothelial cells, we isolated EVs from HBMECs and THP-1 cells under normal- and high-glucose conditions (5.5 and 33 mM). We used NTA, electron microscopy, and LC-MS/MS for EV characterization. HBMECs in RPMI’s default glucose (11 mM) were exposed to 100 ng/mL of each EV condition, and adherent THP-1 CFSE+ cells were quantified. Long-term high glucose activated HBMECs without altering cell viability. Glucose level altered EV secretion, content, and function. For HBMECs, high glucose decreased EV release but shifted their cargo toward metabolism, barrier disruption, and neuronal protein content. For THP-1 cells, high glucose kept the EV release rate and shifted the cargo toward an inflammatory activation profile. Functionally, high-glucose EVs (mainly THP-1-derived) showed a pro-adhesive effect on endothelial cells. Here, we describe the impact of glucose on EV biology and how glucose-altered EVs can influence inflammation and endothelial responses, highlighting the importance of glycemic control in diabetic patients.